Table 2: Efficacy result of JLT on Parkinson’s disease patient at week 32.

JLTPlaceboMean difference95% confidence interval (CI)p value

Movement Disorder Society-Sponsored Revision of Unified PD Rating Scale
(MDS-UPDRS)
Part I total score (nonmotor symptom)−0.46 ± 6.610.84 ± 4.09−1.30−3.37 to 0.770.215
 Q.1 Cognitive−0.07 ± 0.970.00 ± 0.69−0.07−0.39 to 0.250.657
 Q.2 Hallucinations−0.04 ± 0.540.15 ± 0.52−0.18−0.38 to 0.020.075
 Q.3 Depression−0.07 ± 1.030.07 ± 0.72−0.14−0.48 to 0.190.393
 Q.4 Anxious−0.14 ± 0.82−0.02 ± 0.71−0.13−0.41 to 0.160.393
 Q.5 Apathy−0.23 ± 1.36−0.02 ± 0.87−0.21−0.64 to 0.220.327
 Q.6 Dopamine dysregulation−0.13 ± 0.63−0.15 ± 0.520.02−0.20 to 0.240.854
 Q.7 Sleep0.23 ± 1.030.13 ± 1.060.11−0.29 to 0.500.597
 Q.8 Daytime sleep0.16 ± 0.910.11 ± 0.850.05−0.28 to 0.380.759
 Q.9 Pain−0.02 ± 1.300.24 ± 1.05−0.25−0.70 to 0.190.261
 Q.10 Urinary−0.02 ± 0.730.02 ± 0.87−0.04−0.34 to 0.270.813
 Q.11 Constipation−0.13 ± 1.450.96 ± 4.35−1.19−2.30 to 0.130.079
 Q12 Light headedness0.04 ± 1.08−0.04 ± 0.380.72−0.23 to 0.380.641
 Q13 Fatigue−0.04 ± 1.21−0.02 ± 0.97−0.05−0.47 to 0.360.796
Part II total score (motor symptom)0.45 ± 4.131.05 ± 4.58−0.61−2.25 to 1.030.464
Part III total score (motor examination)−0.52 ± 10.131.38 ± 8.27−1.90−5.38 to 1.580.282
Part IV total score (motor complications)0.21 ± 3.560.65 ± 3.42−0.44−1.75 to 0.870.508

Nonmotor Symptom Assessment Scale for Parkinson’s Disease
(NMSS)
Total score−2.27 ± 32.9011.78 ± 28.93−14.05−25.71 to −2.390.019
 D1 total cardiovascular−0.89 ± 3.38−0.15 ± 2.31−0.75−1.84 to 0.350.178
 D2 total sleep/fatigue3.63 ± 7.984.62 ± 7.08−0.99−3.83 to 1.840.490
 D3 total mood/cognition−3.54 ± 14.383.13 ± 9.36−6.66−11.23 to −2.100.005
 D4 total perceptual/hallucinations−0.88 ± 4.170.71 ± 3.04−1.58−2.96 to −0.210.024
 D5 total attention/memory−1.86 ± 6.07−0.15 ± 7.08−1.71−4.20 to 0.770.174
 D6 total gastrointestinal tract−0.86 ± 5.150.98 ± 5.66−1.84−3.87 to 0.200.076
 D7 total urinary1.71 ± 7.571.47 ± 7.120.24−2.52 to 3.010.863
 D8 total sexual function−0.71 ± 4.200.16 ± 3.81−0.88−2.39 to 0.630.251
 D9 total miscellaneous1.13 ± 6.411.00 ± 5.460.13−2.11 to 2.360.912

p value wascomparing the score changes at week 32 between JLT group and placebo group by independent sample t-tests; values are given as mean ± S.D. Values in JLT group and placebo group are the score changed in the same group between week 32 and baseline (score at week 32 minus score at the baseline).